Format

Send to

Choose Destination
Cardiovasc Res. 2014 Aug 1;103(3):423-8. doi: 10.1093/cvr/cvu141. Epub 2014 Jun 20.

Novel concepts in HDL pharmacology.

Author information

1
National Heart, Lung and Blood Institute, NIH, 10 Center Drive, Bldg. 10, Rm. 2C-433, Bethesda, MD, USA aremaley1@cc.nih.gov.
2
Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy Center for the Study of Atherosclerosis, Società Italiana Studio Aterosclerosi, Ospedale Bassini, Cinisello Balsamo, Italy The Blizard Institute, Centre for Diabetes, Barts and The London School of Medicine & Dentistry, Queen Mary University, London, UK.
3
Department of Pharmacological Sciences, Università degli Studi di Milano, Milano, Italy IRCCS Multimedica, Milan, Italy.

Abstract

High-density lipoproteins (HDL) are a target for drug development because of their proposed anti-atherogenic properties. In this review, we will briefly discuss the currently established drugs for increasing HDL-C, namely niacin and fibrates, and some of their limitations. Next, we will focus on novel alternative therapies that are currently being developed for raising HDL-C, such as CETP inhibitors. Finally, we will conclude with a review of novel drugs that are being developed for modulating the function of HDL based on HDL mimetics. Gaps in our knowledge and the challenges that will have to be overcome for these new HDL based therapies will also be discussed.

KEYWORDS:

Atherosclerosis; Cardiovascular disease; Cholesterol; Drugs; HDL

PMID:
24951539
PMCID:
PMC4133558
DOI:
10.1093/cvr/cvu141
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center